

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number  
WO 02/40558 A1

(51) International Patent Classification<sup>7</sup>: C08F 246/00 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/GB01/05030

(22) International Filing Date: 14 November 2001 (14.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 00310178.9 16 November 2000 (16.11.2000) EP

(71) Applicant: BIOCOMPATIBLES LIMITED (GB/GB); Chapman House, Farnham Business Park, Weydon Lane, Farnham, Surrey GU9 8QL (GB).

(72) Inventors: HUGHES, Laurence, Gerald; 2 The Street, Frensham, Farnham, Surrey GU10 3DZ (GB). LEWIS, Andrew, Lennard; Biocompatibles Limited, Chapman House, Farnham Business Park, Weydon Lane, Farnham, Surrey GU9 8QL (GB).

(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/40558 A1

(54) Title: POLYMERS AND POLYMERISATION PROCESSES

(57) **Abstract:** Emulsion polymerisations are described in which the monomers include an ethylenically unsaturated ammonium phosphate ester monomer. The processes may be conducted with high total solids, to produce a polymer latex having a solids content in the range 20 to 60 %, for instance in the range of 25 to 50 % by weight. Preferably comonomers include lower alkyl and higher alkyl methacrylate selected to give desirable glass transition temperatures and coalescing films, zwitterionic comonomers, polyethoxylated comonomers to confer desired biocompatibility and latex stability as well as good wetting for a film formed of the polymer and may contain crosslinking monomers, reactive monomers, anionic monomers and/or cationic monomers. The latexes are stable, even when the process is carried out in the substantial absence of non-polymerisable emulsifier. Coatings formed from the latexes containing zwitterionic comonomer have good biocompatibilising properties.

## POLYMERS AND POLYMERISATION PROCESSES

The present invention relates to polymers formed from radical polymerisation of ethylenically unsaturated monomers including an ammonium phosphate ester zwitterionic monomer, and processes for 5 producing them. In particular, the invention relates to emulsion polymerisation processes for forming high solids emulsions without the incorporation of non-polymerisable emulsifier, and to the use of these emulsions to biocompatibilise substrates.

Yamaguchi *et al* in *Makromol. Chem.* (1989), 190, 1195-1205, 10 describe an oil-in-water emulsion polymerisation of styrene in the presence of polymerisable and non-polymerisable phosphoryl choline compounds as emulsifier. The latex product is stable, the non-polymerisable emulsifiers giving more regular shaped and sized spherical particles than the polymerisable emulsifiers. The polymerisations were conducted to form 15 latexes having around 10 wt% solids. The mole percent of polymerisable emulsifier based on total monomer is around 10%. The base monomer on which the polymerisations were based was styrene.

Sugiyama *et al* in *Polym. J.* (1993) 25(5), 521-527, describe an 20 emulsifier free radical polymerisation of ethylenically unsaturated monomers comprising methylmethacrylate, in the presence of an ethylenically unsaturated ammonium phosphate ester zwitterionic monomer, using a water-soluble initiator. The latex product had a concentration of around 10% by weight polymer. Increasing the amount of zwitterionic monomer resulted 25 in reduced stability of the latex. Whilst low levels of zwitterionic monomer reduced the particle size of microspheres in the latex product as compared to a process containing no such monomer, increasing the level from a mole % of 0.01, based on total monomer, to 0.5 resulted in an increase in the diameter of the microsphere of the product. The microspheres themselves were found to have low levels of adsorption of albumin as compared to 30 polymethylmethacrylate polymerised in the absence of the ammonium phosphate ester zwitterionic monomer.

Sugiyama *et al*, in *J. Polym. Sci., Part A* (1997) 35, 3349-3357, describe oil-in-water emulsion polymerisation of methylmethacrylate, optionally with a comonomer of hydroxypropyl methacrylamide, in the presence of 2-methacryloyloxyethyl-2'-trimethylammoniummethyl phosphate inner salt (MPC). The MPC is present at a level of about 1% based on total ethylenically unsaturated monomer. The latex product had a polymer solids concentration of around 10% by weight. Again the presence of MPC resulted in a decrease in the stability of the latex product with more aggregates being formed. The process was dependent on the choice of initiator, between potassium peroxodisulphate, and 2,2'-azobis[2-(imidazolin-2-yl)propane]dihydrochloride (ABIP). The ABIP initiated products were more influenced by the presence of the MPC monomer in terms of particle size and level of aggregates. In both Sugiyama papers, the reaction mixture was agitated at high speed, with all monomers being included in the reaction vessel at the commencement of the polymerisation. It is not clear how the methylmethacrylate dispersed phase is maintained in suspension during the process for example with no MPC monomer.

Zimehl *et al*, in *Colloid Polym. Sci.* (1990) 268, 924-933 describe emulsion polymerisation of polystyrene using potassium peroxodisulphate in the presence of N-(3-sulphopropyl)-N-methacryloyimidyl propyl (N,N-dimethylammonium betaine) (SPP) at SPP concentrations in the range 5 to 70% by weight based on total monomer. The particle size of the latex product was dependent upon the initiator and the level of betaine comonomer. Again, all of the monomers were dispersed into the aqueous continuous phase before polymerisation was initiated. The solids concentration of product latex was around 10% by weight.

In US-A-3497482 Hwa *et al* describe a copolymerisation of N,N-dimethyl-N-(2-methacryloyloxyethyl)-N-(3-sulphopropyl ammonium inner salt) (SPE), with ethyl methacrylate and acrylamide, in an aqueous continuous phase. Hwa produces a metastable oil-in-water product. He does not describe the particle size of the latex.

In WO-A-93/01221 we describe a range of copolymers of zwitterionic monomer with comonomers such as hydrophobic comonomers, ionic comonomers or reactive comonomers. The copolymers are formed by co-dissolving all the monomers into a solvent in which monomers and polymer are soluble and recovered by precipitation techniques. It is suggested that the product might be a micro emulsion but no examples of emulsion polymerisation are given. The polymers are used to coat substrates in order to improve their biocompatibility. Whilst improvements in biocompatibility may be achieved by using molar percentages of 1% or lower of zwitterionic monomer, based on total ethylenically unsaturated monomer, it is often found that at least 20 mol% zwitterionic monomer is needed for satisfactory levels of improved biocompatibility. The higher the level of zwitterionic monomers, the greater the expense.

Zwitterionic polymers made by the techniques such as are described in WO-A-93/01221, may be blended with physically or mechanically desirable copolymers to provide blends which have good biocompatibilising properties. The level of zwitterionic monomer in the total blend is reduced, thereby rendering the product more cost effective than single component zwitterionic polymer products. Such blends are described in, for instance, WO-A-93/02652 and PCT/GB00/03985 (unpublished at the priority date of this application). PCT/GB00/03985 describes blends of MPC copolymers with higher alkyl methacrylate comonomers, blended with alkyl(meth)acrylate polymers. Such blends, co-dissolved in a suitable organic solvent may be coated onto a surface to form a coating having micro-domains of relatively hydrophilic and relatively hydrophobic character. The blends may express higher levels of phosphorylcholine groups at the surface than in the bulk of the coating. This should allow the properties of a substrate coated with the polymer to be tailored for particular biocompatibility.

It would be desirable to produce a latex having high solids, in which a zwitterionic monomer is one of the ethylenically unsaturated monomers. It would furthermore be desirable to produce a copolymer of an ammonium

phosphate ester zwitterionic monomer including low levels of that monomer. It would be desirable to carry out an emulsion polymerisation to produce a stable latex product having a small particle size, and low particle size distribution and which forms coatings having desirable biocompatibilising properties without using high levels of ammonium phosphate ester zwitterionic monomer.

In a new emulsion polymerisation process according to the invention, a mixture of ethylenically unsaturated monomers including water-insoluble monomers is polymerised in the dispersed phase of an oil-in-water emulsion in the presence of a water-soluble radical initiator, ethylenically unsaturated monomers including an ammonium phosphate ester zwitterionic monomer the process being characterised by being carried out at component concentrations to give a latex product having a polymer solids concentration of at least 20% by weight.

In the new process, the solids concentration of the product is usually no more than 60%, preferably in the range 25 to 50% by weight.

The process of the invention may be carried out in the presence of non-polymerisable emulsifiers and/or stabilisers. It is found that it is possible for the emulsion and latex product to be adequately stabilised by the presence of the ammonium phosphate ester zwitterionic monomer, optionally in combination with other surface active monomers. The process is preferably carried out therefore in the substantial absence of non-polymerisable surfactant/emulsifier and stabiliser.

The ammonium phosphate ester zwitterionic monomer is preferably included in an amount in the range 0.01 to 5% by weight, based on the total weight of monomers. More preferably the level of the zwitterionic monomer is in the range 0.05 to 2% by weight, for instance 0.1 to 1% by weight.

The zwitterionic monomer preferably has the general formula I




in which X is the ammonium phosphate ester zwitterionic group;

B is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and

Y is an ethylenically unsaturated group selected from  $\text{H}_2\text{C}=\text{CR-CO-A-}$ ,  
 5  $\text{H}_2\text{C}=\text{CR-C}_6\text{H}_4\text{-A}^1\text{-}$ ,  $\text{H}_2\text{C}=\text{CR-CH}_2\text{A}^2\text{-}$ ,  $\text{R}^2\text{O-CO-CR=CR-CO-O-}$ ,  $\text{RCH=CH-CO-O-}$ ,  
 $\text{RCH=C(COOR}^2\text{)CH}_2\text{-CO-O-}$ ,

10



A is -O- or  $\text{NR}^1$ ;

$\text{A}^1$  is selected from a bond,  $(\text{CH}_2)_n\text{A}^2$  and  $(\text{CH}_2)_n\text{SO}_3^-$  in which n is 1 to 12;

15  $\text{A}^2$  is selected from a bond, -O-, O-CO-, -CO-O-, -CO-NR<sup>1</sup>-, -NR<sup>1</sup>-CO, -O-CO-NR<sup>1</sup>-, and -NR<sup>1</sup>-CO-O-;

R is hydrogen or  $\text{C}_{1-4}$  alkyl;


$\text{R}^1$  is hydrogen,  $\text{C}_{1-4}$  alkyl or BX; and

$\text{R}^2$  is hydrogen or  $\text{C}_{1-4}$  alkyl.

20 Generally in the zwitterionic group X, the anion is closer to B than the cation. However in some zwitterions, the cation is closer to the group B than is the anion (called hereinafter phosphobetaines).

Preferably X is a group of the general formula II

25




30

in which  $\text{R}^3$  is alkanediyl of 1 or more, preferably 2-6 carbon atoms optionally containing one or more ethylenically unsaturated double or triple bonds, disubstituted-aryl (arylene), alkylene arylene, arylene alkylene, or alkylene aryl alkylene, cycloalkanediyl, alkylene cycloalkyl, cycloalkyl alkylene or

alkylene cycloalkyl alkylene, and optionally contains one or more fluorine substituents and/or one or more functional groups; and

either the groups R<sup>4</sup> are the same or different and each is hydrogen or alkyl of 1 to 4 carbon atoms, preferably methyl, or aryl, such as phenyl, or  
 5 two of the groups R<sup>4</sup> together with the nitrogen atom to which they are attached form an aliphatic heterocyclic ring containing from 5 to 7 atoms, or the three groups R<sup>4</sup> together with the nitrogen atom to which they are attached form a fused ring structure containing from 5 to 7 atoms in each ring, and optionally one or more of the groups R<sup>4</sup> is substituted by a  
 10 hydrophilic functional group.

Alternatively X may be a group of the general formula III



15

in which the group R<sup>5</sup> are the same or different and each is hydrogen, C<sub>1-4</sub> alkyl, such as methyl, or aryl, such as phenyl;

R<sup>6</sup> alkanediyl of 1 or more, preferably 2-6 carbon atoms optionally containing one or more ethylenically unsaturated double or triple bonds,  
 20 disubstituted-aryl (arylene), alkylene arylene, arylene alkylene, or alkylene aryl alkylene, cycloalkanediyl, alkylene cycloalkyl, cycloalkyl alkylene or alkylene cycloalkyl alkylene, optionally contains one or more fluorine substituents and/or one or more functional groups;

R<sup>7</sup> is hydrogen, or an optionally substituted C<sub>1-18</sub> alkyl, C<sub>2-18</sub> alkenyl, C<sub>2-18</sub> alkynyl, C<sub>6-24</sub> aryl or C<sub>7-24</sub> aralkyl group.

In a group of the general formula III, R<sup>7</sup> is preferably other than hydrogen and is more preferably an unsubstituted C<sub>1-6</sub> alkyl, C<sub>6-12</sub> aryl or C<sub>7-12</sub> aralkyl group. Any substituents in a substituted group R<sup>7</sup> are usually fluorine atoms, or hydroxyl or C<sub>1-4</sub> alkoxy groups.

30 In the new emulsion polymerisation process the monomers preferably include at least 50% by weight of ethylenically unsaturated polymerisable

monomers. Examples of suitable monomers are compounds selected from the group consisting of  $C_{1-12}$ -alkyl(alk)acrylates,  $C_{2-12}$ -alkyl- and -dialkyl-(alk)acrylamides, water insoluble vinyl esters or ethers, allylic compounds, maleic or fumaric esters or imides, aconitic compounds, styrenic compounds, 5 eg styrene, and mixtures thereof.


As is known in emulsion polymerisation techniques, the choice of monomers affects the physical properties of the mixture, in particular whether the polymer particles of the product are able to coalesce after removal of water, for instance to form stable film coatings. It is preferred that 10 the hydrophobic compounds are selected for their ability to form films at suitable temperatures for coating processes.

It is found that particularly desirable characteristics are achieved by using a blend of hydrophobic compounds, which would tend to confer different properties of hardness on the resultant polymer. Monomers which 15 tend to produce hard polymers are lower alkyl(meth)acrylate especially methylmethacrylate. Compounds which tend to produce softer copolymers are alkylacrylates and methacrylates having straight or branched alkyl groups with at least 4 carbon atoms, such as butyl, hexyl, 2-ethylhexyl or n-octyl groups. Preferably the hydrophobic compound comprises a mixture of 20 methylmethacrylate with a  $C_{4-8}$  alkyl acrylate.

The emulsion polymerisation itself and the properties of the product, especially the biocompatibility of films produced from the emulsion, are beneficially affected by incorporating a zwitterionic comonomer. The zwitterionic comonomer preferably comprises as cation a quaternary 25 ammonium or phosphonium group but may comprise a tertiary sulphonium group. The anion may be a sulphonate, sulphate, phosphonate, or carboxylate anion, most preferably a sulphonate or carboxylate anion. Most preferably the comonomer is a sulpho- or carboxy-betaine monomer. The zwitterionic comonomer is suitably a compound of the general formula IV

in which  $Y^1$  is an ethylenically unsaturated group selected from  $H_2C=CR^8-CO-A^6-$ ,  $H_2C=CR^8-C_6H_4-A^3-$ ,  $H_2C=CR^8-CH_2A^4-$ ,  $R^9O-CO-CR^8=CR^8-CO-O-$ ,  $R^8CH=CH-CO-O-$ ,  $R^8CH=C(COOR^9)CH_2-CO-O-$ ,

5



$A^6$  is  $-O-$  or  $NR^{10}-$ ;  
10  $A^3$  is selected from a bond,  $(CH_2)_m A^4$  and  $(CH_2)_m SO_3-$  in which  $m$  is 1 to 12;


$A^4$  is selected from a bond,  $-O-$ ,  $O-CO-$ ,  $CO-O$ ,  $-CO-NR^{10}-$ ,  $-NR^{10}-CO$ ,  $-O-CO-NR^{10}-$ , and  $NR^{10}-CO-O-$ ;

15  $R^8$  is hydrogen or  $C_{1-4}$  alkyl;  
 $R^{10}$  is hydrogen,  $C_{1-4}$  alkyl or  $B^1X^1$ ;  
 $R^9$  is hydrogen or  $C_{1-4}$  alkyl;  
 $B^1$  is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and

20  $X^1$  is a zwitterionic group other than an ammonium phosphate ester.  
The zwitterionic group  $X^1$  may have, as anion a carboxylate group, a sulphate group, a sulphonate group or a phosphonate group, preferably carboxylate or, more preferably a sulphonate group. The zwitterionic group  $X^1$  may have as cationic group an ammonium, phosphonium or sulphonium group, preferably an ammonium group.


25 A preferred zwitterionic group  $X^1$  has the general formula V

30



where the groups  $R^{11}$  are the same or different and each is hydrogen or  $C_{1-4}$  alkyl and  $s$  is from 2 to 4. Preferably the groups  $R^{11}$  are the same. It is also preferable that at least one of the groups  $R^{11}$  is methyl, and more preferable that the groups  $R^{11}$  are both methyl. Preferably  $s$  is 2 or 3, more preferably 3.

Alternatively the zwitterionic group may be an amino acid moiety in which the alpha carbon atom (to which an amine group and the carboxylic acid group are attached) is joined through a linker group to the backbone of the biocompatible polymer. Such groups may be represented by the general formula VI




in which  $A^5$  is a valence bond, -O-, -S- or -NH-, preferably -O-,  $R^{12}$  is a valence bond (optionally together with  $A^5$ ) or alkanediyl, -C(O)alkylene-, NHCOalkylene or -C(O)NHalkylene, preferably alkanediyl and preferably containing from 1 to 6 carbon atoms; and

the groups  $R^{13}$  are the same or different and each is hydrogen or alkyl of 1 to 4 carbon atoms, preferably methyl, or two or three of the groups  $R^{13}$ , together with the nitrogen to which they are attached, form a heterocyclic ring of from 5 to 7 atoms, or the three group  $R^{13}$  together with the nitrogen atom to which they are attached form a fused ring heterocyclic structure containing from 5 to 7 atoms in each ring.

Alternatively the zwitterion may be a carboxy betaine -  $N^{\oplus}(\text{R}^{14})_2(\text{CH}_2)_r\text{COO}^{\ominus}$  in which the  $\text{R}^{14}$  groups are the same or different and each is hydrogen or  $C_{1-4}$  alkyl and  $r$  is 2 to 6, preferably 2 or 3.

In another embodiment, the zwitterionic group  $X^1$  has the general formula VII



W is S, PR<sup>16</sup> or NR<sup>16</sup>;

5 the or each groups R<sup>16</sup> is hydrogen or alkyl of 1 to 4 carbon atoms or the two groups R<sup>16</sup> together with the heteroatom to which they are attached form a heterocyclic ring of 5 to 7 atoms;

R<sup>17</sup> is alkanediyl of 1 to 20, preferably 1 to 10, more preferably 1 to 6 carbon atoms;

10 A<sup>7</sup> is a bond, NH, S or O, preferably O; and

R<sup>18</sup> is a C<sub>1-12</sub> alkyl, C<sub>7-18</sub> aralkyl or C<sub>6-18</sub> aryl group or, where A<sup>7</sup> is other than a bond, is a C<sub>1-12</sub>-alkoxy, C<sub>6-18</sub>-aryloxy or C<sub>7-18</sub>-aralkoxy group.

In compounds comprising a group of the general formula VII, it is preferred that

15 W is NR<sup>16</sup>;

each R<sup>16</sup> is C<sub>1-4</sub> alkyl; and

R<sup>17</sup> is C<sub>2-6</sub> alkanediyl.

In all embodiments, in the zwitterionic comonomer of the general formula IV Y<sup>1</sup> is preferably H<sub>2</sub>C=CR<sup>8</sup>-CO-A<sup>3</sup>-. Such acrylic moieties are preferably methacrylic, that is in which R<sup>8</sup> is methyl, or acrylic, in which R<sup>8</sup> is hydrogen. Whilst the compounds may be acrylamido compounds (in which A is NR<sup>10</sup>), in which case R<sup>10</sup> is preferably hydrogen, or less preferably, methyl, most preferably the compounds are esters, that is in which A<sup>3</sup> is O.

Suitable examples of comonomer of the general formula IV are SPP and

25 SPE.

In monomers of the general formula IV, especially where Y is the preferred acrylic group, B<sup>1</sup> is most preferably an alkanediyl group. Whilst some of the hydrogen atoms of such group may be substituted by fluorine atoms, preferably B<sup>1</sup> is an unsubstituted alkanediyl group, most preferably a straight chain group having 2 to 6 carbon atoms.

Where a zwitterionic comonomer is included, the ratio of that comonomer to ammonium phosphate ester zwitterionic monomer is preferably in the range (1 to 50):1, more preferably in the range (5 to 20):1.

The ethylenically unsaturated monomers may further comprise

5 hydrophilic monomer, for instance relatively water-soluble monomers. Hydrophilic monomers are preferably selected from the group consisting of C<sub>1-4</sub>-hydroxyalkyl(meth)acrylates, C<sub>1-4</sub>-hydroxyalkyl(meth)acrylamides, C<sub>1-3</sub>-alkoxy-C<sub>2-4</sub>-alkyl(meth)acrylates, C<sub>1-3</sub>-alkoxy-C<sub>2-4</sub>-alkyl(meth)acrylamides, C<sub>1-3</sub>-alkoxy-oligoethoxy(meth)acrylates, C<sub>1-4</sub>-dihydroxyalkyl(meth)acrylates, 10 N-mono- or N,N- di- C<sub>1-2</sub> alkyl (meth)acrylamides, N-vinylactams, and C<sub>2-4</sub>-hydroxyalkyl-oligoethoxy(meth)acrylates and mixtures thereof.

It has been found to be particularly useful to include, as a hydrophilic monomer, a monomer comprising an oligoethoxy moiety, that is selected from C<sub>1-3</sub>-alkoxy-oligoethoxy(meth)acrylates and C<sub>2-4</sub>-hydroxyalkyl-oligoethoxy(meth)acrylates, more preferably the alkoxy terminated compounds. Preferably an alkoxy group is methoxy or ethoxy. Such compounds preferably have 5 to 50 ethoxy groups, for instance in the range 10 to 20 methoxy groups. Oligoethoxylated polymerisable compounds improve the stability of the emulsion during the process, as well as the latex product, and may confer desirable wetting characteristics on a product polymer as well as useful biocompatibility.

A hydrophilic monomer is preferably included in an amount in the range 0.1 to 50% by weight of total monomers, more preferably an amount in the range 1 to 25% by weight, for instance an amount in the range 5 to 20% 25 by weight. An oligo ethoxylated comonomer is preferably included in an amount in the range 1 to 20% by weight, more preferably in the range 5 to 10% by weight. It is often used in conjunction with one or more other hydrophilic monomers, such that the total amount of hydrophilic monomer is in the range 5 to 50% by weight.

30 The stability of the emulsion during polymerisation is found to be improved if the pH of the emulsion is maintained slightly acidic, that is has a

pH less than 7, more preferably in the range 4 to 6.8, for instance about 5. Whilst the acidity may be achieved by adding a non-polymerisable acid for instance a mineral acid, to the emulsion, it is preferable to include a polymerisable acid as one of the ethylenically unsaturated monomers.

5 Preferably an ethylenically unsaturated acid is selected from fumaric acid, maleic acid, vinyl sulphonic acid and styrene sulphonic acid, more preferably selected from acrylic and methacrylic acids, and is most preferably methacrylic acid.

Where acidic monomer is included, it is present in an amount in the 10 range 0.1 to 5% by weight, more preferably in the range 0.2 to 2% by weight, based on the total weight of monomers.

Other compounds, especially other monomers may be included in the polymerisation mixture, for instance to achieve desired product characteristics.

15 It may also be desirable to include non-polymerisable components in the polymerisation mixture, for instance in the continuous aqueous phase or in the dispersed oil phase, or at the interface. Non-polymerisable emulsifiers and suspending agents may be included, but are preferably not included. Drugs, especially water-insoluble, oil-soluble drugs may be added whereby 20 they may become absorbed in the latex particles of the product.

It may be desirable to include cationic monomer, in order to provide a product polymer having an overall cationic charge.

As described in our application number WO-A-93/01221 and WO-A-98/22516, the presence of cationic groups in a polymer may confer desirable 25 binding properties either to underlying counterionically charged surfaces, or to anionic compounds which may be contacted with a surface coated with the polymer to achieve desirable results.

A cationic monomer is preferably a compound of the general formula

VIII


30

$Y^2$     $B^2$    Q

VIII

in which  $Y^2$  is an ethylenically unsaturated group selected from  $H_2C=CR^{19}-$ ,  $CO-A^8-$ ,  $H_2C=CR^{19}-C_6H_4-A^9-$ ,  $H_2C=CR^{19}-CH_2A^{10}$ ,  $R^{21}O-CO-CR^{19}=CR^{19}-CO-O-$ ,  $R^{19}CH=CH-CO-O-$ ,  $R^{19}CH=C(COOR^{21})CH_2-CO-O-$ ,

5



$A^8$  is  $-O-$  or  $-NR^{20}-$ ;

10  $A^9$  is selected from a bond,  $(CH_2)_qA^{10}$  and  $(CH_2)_qSO_3^-$  in which  $q$  is 1 to 12;

$A^{10}$  is selected from a bond,  $-O-$ ,  $O-CO-$ ,  $-CO-O-$ ,  $-CO-NR^{20}-$ ,  $-NR^{20}-$ ,  $CO$ ,  $O-CO-NR^{20}-$ , and  $NR^{20}-CO-O-$ ;

$R^{19}$  is hydrogen or  $C_{1-4}$  alkyl;

15  $R^{20}$  is hydrogen,  $C_{1-4}$  alkyl or  $BX$ ;

$R^{21}$  is hydrogen or  $C_{1-4}$  alkyl;

$B^2$  is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and

20  $Q$  is  $-N^eR^{22}_3$ ,  $-P^eR^{23}_3$  or  $-S^eR^{23}_2$  in which either the groups  $R^{22}$  are the same or different and each is hydrogen, alkyl of 1 to 6 carbon atoms, preferably methyl,  $C_{1-6}$  hydroxyalkyl, aryl, such as phenyl, or  $C_{7-12}$  aralkyl, or two of the groups  $R^{22}$  together with the nitrogen atom to which they are attached form an aliphatic heterocyclic ring containing from 5 to 7 atoms, or the three groups  $R^{22}$  together with the nitrogen atom to which they are attached form a fused ring structure containing from 5 to 7 atoms in each ring, and optionally one or more of the groups  $R^3$  is substituted by a hydrophilic functional group, and

the groups  $R^{23}$  are the same or different and each is  $R^{22}$  or a group

30  $OR^{22}$ , where  $R^{22}$  is as defined above *mutatis mutandis*.

In the cationic monomer of the general formula VIII Q is preferably -  $N^{\oplus}R^{22}_3$ , in which each  $R^{22}$  is a  $C_{1-4}$  alkyl group, preferably each  $R^{22}$  being methyl. The group  $Y^2$  is preferably an acrylic group, that is of the formula  $H_2C=CR^{19}COA^8$ . In such groups  $R^{19}$  is either hydrogen or methyl, preferably 5 methyl, and  $A^8$  is preferably -O-.  $B^2$  is preferably a  $C_{2-618}$  alkanediyl group, more preferably a  $C_{2-6}$  alkanediyl. Examples of suitable cationic monomers are 2-(N,N-dimethylamino)ethyl methacrylate methyl chloride or methyl sulphate salt, and 2-(N,N-dimethyl amino) ethyl acrylate methyl chloride or methyl sulphate salt.

10 A cationic monomer may be included in an amount in the range 0.1 to 25% by weight, more preferably an amount in the range 1 to 20 % by weight, most preferably in an amount in the range 2 to 15% by weight.


15 Other monomers which may useful be included in the mixture include functional monomers, comprising reactive groups which are useful to provide attachment points for ligands or for underlying substrate surfaces having co-reactive functional groups, or to provide inter- or intra-molecular crosslinkability. Such functional groups may react with co-reactive groups derived from other functional monomers such as hydroxyl or amine group containing monomers.

20 Preferably a reactive monomer has the general formula IX



in which  $Y^3$  is an ethylenically unsaturated group selected from  $H_2C=CR^{24}-$   $CO-A^{11}-$ ,  $H_2C=CR^{24}-C_6H_4-A^{12}-$ ,  $H_2C=CR^{19}-CH_2A^{13}$ ,  $R^{26}O-CO-CR^{24}=CR-CO-O-$ ,  $R^{24}CH=CH-CO-O-$ ,  $R^{24}CH=C(COOR^{26})CH_2-CO-O-$ ,

25



30  $A^{11}$  is -O- or -NR<sup>25</sup>;

$A^{12}$  is selected from a bond,  $(CH_2)_r A^{13}$  and  $(CH_2)_r SO_3^-$  in which  $r$  is 1 to 12;

$A^{13}$  is selected from a bond, -O-, O-CO-, CO-O, -CO-NR<sup>25</sup>-, -NR<sup>25</sup>-CO, -O-CO-NR<sup>25</sup>-, and NR<sup>25</sup>-CO-O-;

5  $R^{24}$  is hydrogen or  $C_{1-4}$  alkyl;

$R^{25}$  is hydrogen,  $C_{1-4}$  alkyl or  $B^3 Q^1$ ;

$R^{26}$  is hydrogen or  $C_{1-4}$  alkyl;

10  $B^3$  is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents.

15  $Q^1$  is a reactive group selected from the group consisting of aldehyde groups; silane and siloxane groups containing one or more substituents selected from halogen atoms and  $C_{1-4}$ -alkoxy groups; hydroxyl; amino; carboxyl; epoxy; -CHOHCH<sub>2</sub>Hal (in which Hal is selected from chlorine, bromine and iodine atoms); succinimido; tosylate; triflate; imidazole carbonyl amino; optionally substituted triazine groups; cinnamyl; ethylenically and acetylenically unsaturated groups; acetoacetoxy; methylol; and chloroalkylsulphone groups; acetoxy; mesylate; carbonyl di(cycloalkyl carbodiimidoyl; and oximino.

20 Preferred groups  $Q^1$  are aldehyde, reactive silane and siloxane, amino, epoxy, CHOHCH<sub>2</sub>Hal (in which Hal is halogen), succinimido, tosylate, triflate, imidazolecarbonyl amino and optionally substituted triazine groups. Most preferably  $Q^1$  is a trialkoxy silyl group, such as a trimethoxysilyl group.

25 In the reactive monomer of the general formula IX the ethylenically unsaturated group  $Y^3$  is preferably and acrylic type group, that is a group  $H_2C=CR^{24}A^{11}-$ ,  $R^{24}$  preferably being hydrogen or, most preferably, methyl and  $A^{11}$  preferably being -O-. Preferred groups  $B^3$  are  $C_{2-18}$  alkanediyl, most preferably  $C_{2-6}$ - alkanediyl.

30 The emulsion polymerisation of the invention may be carried out in a single step, in which all of the monomers are dispersed into an aqueous

continuous phase and agitation applied to form an emulsion having suitable sized droplets followed by initiation of polymerisation. However, optimum particle size distribution is achieved if a two-step process is used, in a first step of which a seed polymer is formed, and in the second step the seeds 5 are grown. In such a process, the seed monomers are dispersed into the aqueous phase and polymerisation is initiated. To the seed polymer latex, the remaining monomers and additional initiator are added, so that polymerisation is initiated at the seeds. Monomer travels from monomer droplets to the polymer seeds.

10 Preferably in a process involving a seed polymerisation step, the monomers from which the seed polymer is formed comprise at least a portion of the ammonium phosphate ester zwitterionic monomer which is preferably added to the polymerisation mixture in the form of an aqueous solution. The seed monomers must include at least a portion of the water-15 insoluble monomers. These monomers are dispersed into the aqueous continuous phase in the presence of the ammonium phosphate ester zwitterionic monomer whereby an emulsion of seed monomer is formed. Polymerisation is initiated by radical initiator by a water-soluble initiator.

20 After seed polymerisation has continued until the yield of polymer is at least 1% based on solids, seed growth emulsion polymerisation step is then carried out by adding further monomer including at least a portion of the remaining water-insoluble monomer to the emulsion, along with further water-soluble initiator. It may be desirable for the polymer formed after the initial seed polymerisation step to have a substantially constant composition. 25 In this case, it is desirable for a water-immiscible liquid containing the water-insoluble monomers and other compatible comonomers and for this mixture to be added in a single addition step or continuously over an extended period to the aqueous reaction mixture. If any of the monomers selected components for the ethylenically unsaturated monomers are immiscible with 30 the water-insoluble monomer blend, it may be desirable for the or all of the

monomers of that type to be added separately to the polymerisation mixture, for instance in the form of an aqueous solution.

It is preferred that the monomer blend be added over a period during which polymerisation continues to the reaction mixture, and that

5 polymerisation be continued after all of the monomer has been added.

During the monomer feed period, it is preferred for initiator to be continuously added to the reaction mixture. Preferably a portion of initiator is retained until after all of the monomer has been added to the mixture and is then included to minimise the level of residual unpolymerised monomer in

10 the product.

It may be desirable for the polymerisation to form a core-shell morphology. Such morphologies are generally achieved by carrying out the polymerisation, generally after a seed polymerisation step, in two or more phases. Generally the polymer formed in the two or more phases differs in

15 terms of the monomers used and/or their ratios. Using such techniques it is possible to form a product latex in which the polymer particles have tailored characteristics with cores and shells of desired hardness, desired hydrophilicity or desired porosity. Such characteristics are achieved by selecting monomers according to their glass transition temperatures,

20 hydrophilicities, or crosslinkability. To achieve a low porosity product, for instance, it may be desirable to incorporate di-, tri- or higher-functional ethylenically unsaturated monomers, or to include functional monomers which may be reacted with the same or different functional monomers during or after polymerisation to provide intermolecular crosslinks.

25 Core/shell morphology may be achieved by changing the composition of monomers added to the polymerisation mixture during the polymerisation process. Thus monomers for forming the core should be added and polymerised in the mixture before addition of monomers for forming the shell.

30 In one particular embodiment of the process of the invention, a zwitterionic comonomer is included as part of the ethylenically unsaturated monomer and is added to the polymerisation mixture as a component of the

aqueous initiator composition, and is preferably added continuously over a monomer feed period during which water-insoluble monomer blend is separately added to the polymerisation mixture. Preferably a monomer feed period is conducted for a period in the range 5 to 1200 minutes, most 5 preferably in the range 30 to 240 minutes.

By the use of the ammonium phosphate ester zwitterionic monomer it has been found possible to conduct the emulsion polymerisation under conditions such that high solid content latex products are formed. Thus the 10 level of polymer in the latex product may be higher than 20% by weight, for instance up to 6%, preferably in the range 20 to 60% by weight, without adversely affecting the stability nor viscosity. Such latexes are convenient to handle. Whilst water may be evaporated from the product latex to achieve such high solids materials, or the polymer particles may be recovered by agglomeration or coagulation techniques and redissolved into water, 15 preferably no such steps are carried out to achieve the 20 to 50% by weight solids latex. Alternatively the latex may be diluted before use or compounded with other ingredients compatible with its end use, such as water, other latices or coalescing aids. Coalescing aids may assist in the film formation of the final product, especially where the polymer is film 20 forming at a higher temperature than room temperature. One suitable component is a latex preservative, for instance which inhibits bacterial growth or is a biocide or fungicide, suitably an alcohol such as benzyl alcohol.

It is believed that this is the first time that ammonium phosphate ester 25 zwitterionic monomers have been used in emulsion polymerisation processes including a seed polymer formation phase. According to a further aspect of the invention there is provided a seeded emulsion polymerisation process in which a mixture of ethylenically unsaturated monomers including water-insoluble monomers and an ammonium phosphate ester zwitterionic 30 monomer is copolymerised in the dispersed phase of an oil-in-water emulsion in the presence of a water-soluble radical initiator comprising the steps

- i) providing an aqueous solution comprising at least a portion of the ammonium phosphate ester zwitterionic monomer and a portion of the initiator;
- ii) forming a dispersed phase comprising a monomer seed composition comprising at least a portion of the water-insoluble monomers to form a seed emulsion;
- 5 iii) initiating polymerisation of the seed emulsion whereby a seed latex is formed;
- iv) providing a seed growth monomer mixture comprising the remaining water-insoluble monomers; and
- 10 v) adding the monomer cell mixture to the seed polymer latex and initiating polymerisation of the monomers of the seed growth mixture in the dispersed seeds, to form a product polymer latex.

15 In the seeded emulsion polymerisation process it is preferred that all of the ammonium phosphate ester zwitterionic monomer is present in the seed polymerisation mixture.

Whilst the novel seeded polymerisation process may be carried out to provide a relatively low solid product polymer latex of less than 20%, for instance in the range 2 to 20%, it is possible to carry out the process under 20 conditions such that the product latex has a solid concentration in the range 20 to 60% by weight.

25 The seeded polymerisation process allows formation of a product polymer latex having very low distribution of product particle size. The particle size may be controlled by the levels of seed monomer, initiator and seed growth monomer, as well as the choice of the type and amount of ammonium phosphate ester zwitterionic monomer, as well as other monomer components. Preferably the product latex has dispersed phase with average particle diameter of less than 1  $\mu\text{m}$ , more preferably less than 500 nm, most preferably in the range 100 to 400 nm. Preferably the polydispersity of 30 particle size (number average over weight average diameter) is in the range 1.0 to 2.0.

It is preferred that the level of initiator for these low particle size distributions is in the range 0.001 to 0.5 weight % based on solids, preferably in the range 0.01 to 0.1 weight %. Preferably the ratio of weight of combined seed monomer to seed growth polymer is in the range 1:99 to 5 99:1, preferably in the range 1:50 to 1:10.

The seeded emulsion polymerisation technique may be used to form a core-shell polymer product, using the techniques described above in connection with the first aspect of the invention. In such a process the seed growth monomers comprise two or more mixtures including a core mixture 10 and a shell mixture, usually differing in terms of composition.

The seeded emulsion polymerisation process has preferred components as described above in connection with the first aspect of the invention.

The polymer latex product of the first aspect of the invention forms a 15 further aspect of the invention. A novel stable latex comprises a dispersion of polymer particles in aqueous continuous phase, having a polymer concentration in the range 20 to 60% by weight based on the total weight of the latex, an average particle diameter of less than 1  $\mu\text{m}$ , the polymer being formed from radical polymerised ethylenically unsaturated monomers 20 comprising water-insoluble monomer and ammonium phosphate ester zwitterionic monomer.

The novel latex may further comprise additional components. For instance it may be desirable to add to the latex suspended particulate solids selected from organic and inorganic water-insoluble materials. Particularly 25 preferred are suspended inorganic solids such as pigments, preferably having particle sizes less than 1  $\mu\text{m}$ . The latex may additionally comprise dissolved or miscible components for instance to improve the storage stability of the latex, or to provide additional properties for the product of the final dried film. For instance, drugs may be incorporated into the latex, 30 either by adding a suspension or an aqueous or organic solvent-based solution to the latex. Colouring agents may also be included.

The novel latex, or the product of one of the novel polymerisation processes, may be used as a coating composition.

According to a further aspect of the invention there is provided a novel coating process in which such a dispersion is coated onto a substrate 5 to form a liquid coating on a surface thereof, and water is removed from the liquid coating to form a stable solid polymer coating on the said surface. Generally water is removed by evaporation although contact with precipitating solvents may also be utilised. Evaporation may be conducted at raised temperature and/or reduced pressure, and coalescing acids, such 10 as alcohols, esters, glycols or other ethers, may be used to provide added control over film formation.

Preferably water removal is conducted under conditions of raised temperature under which the polymer particles coalesce to form a coherent and substantially void-free, preferably clear film.

15 The dried film may be subjected to additional steps such as curing, for instance by heating, especially where the monomers include a cross-linking monomer such as monomers of the general formula IX above. Gamma or other e.m. radiation or ethyleneoxide treatment may also be carried out to cure and/or sterilise the film.

20 The product films have particularly desirable biocompatibilising properties. They are generally used in environments in which the coated surface is contacted with aqueous liquids, generally biological liquids, for instance containing dissolved protein or suspended cells, such as bacterial or, preferably, blood cells. Preferably such liquids are selected from blood 25 and serum.

According to a further aspect of the invention there is provided a novel biocompatibilising process in which a substrate is biocompatibilised by coating it with a latex according to the third aspect of the invention or which is the product of a process according to the first or second aspects of the 30 invention, water is removed, to leave a stable coating of solid polymer on the surface.

Some of the monomer compositions used in the first and second aspects of the invention are believed to be novel in themselves. Whilst the novel emulsion polymerisation techniques are believed to optimise the polymer properties, it is possible that other techniques may be suitable for 5 copolymerising these monomers to form polymers having desirable characteristics. Such novel polymers are obtainable by radical polymerisation of ethylenically unsaturated monomers comprising:

- i) 0.1 to 25% by weight of an ammonium phosphate ester zwitterionic monomer;
- 10 ii) 0.1 to 25% by weight of a zwitterionic comonomer different to i); and
- iii) 25 to 99% of a hydrophobic monomer.

Preferably this hydrophobic monomer is a compound as described above. Most preferably it is selected from the group consisting of C<sub>1-12</sub>-alkyl(alk)acrylates, C<sub>2-12</sub>-alkyl- and -dialkyl-(alk)acrylamides and styrene, and 15 mixtures thereof.

The novel polymers may further comprise:

- iv) 0.01 to 50% by weight hydrophilic monomer, preferably selected from the group consisting of C<sub>1-4</sub>-hydroxyalkyl(meth)acrylates, C<sub>1-4</sub>-hydroxyalkyl(meth)acrylamides, C<sub>1-3</sub>-alkoxy-C<sub>2-4</sub>-alkyl(meth)acrylates, C<sub>1-3</sub>-alkoxy-C<sub>2-4</sub>-alkyl(meth)acrylamides, C<sub>1-3</sub>-alkoxy-oligoethoxy(meth)acrylates, 20 C<sub>1-4</sub>-dihydroxyalkyl(meth)acrylates, N-mono- or N,N- di- C<sub>1-2</sub> alkyl (meth)acrylamides, N-vinylactams, and C<sub>2-4</sub>-hydroxyalkyl-oligoethoxy(meth)acrylates and mixtures thereof.

25 The hydrophilic monomer preferably comprises an oligoethoxylated compound, preferably in an amount in the range 0.1 to 10% by weight based on the total weight of monomer. Preferably such a monomer is selected from C<sub>1-3</sub>-alkoxy-oligoethoxy(meth)acrylates and C<sub>2-4</sub>-hydroxyalkyl-oligoethoxy(meth)acrylates, more preferably the alkoxy terminated 30 compounds.

In one embodiment the novel polymer comprises 0.01 to 20% by weight, more preferably 0.1 to 5% by weight reactive monomer, comprising the general formula X defined above.

In another embodiment of the invention, the monomers include 0.01 to 5 10%, preferably 0.1 to 2% by weight anionic monomer, preferably selected from fumaric acid, maleic acid, vinyl sulphonic acid and styrene sulphonic acid, more preferably selected from acrylic and methacrylic acids, and is most preferably methacrylic acid.

10 In another embodiment of the polymer of the invention, the monomers include 1 to 25%, preferably 2 to 15% cationic monomer, preferably a compound of the general formula VIII defined above.

15 There is also provided in the present invention a film formed of the novel polymer. Preferably the film is a coherent, substantially void free film, preferably in the form of a coating on a surface of a substrate. The substrate is preferably the surface of a device for use in contact with biological fluids or organs, especially a device used in contact with aqueous liquids susceptible to fouling by proteins, carbohydrates, microbes or cells of higher organisms, cell culture substrates, assay devices, biosensors etc. Most 20 preferably the substrate is the surface of a medical device, for instance an ophthalmic device such as a contact lens, a corneal onlay or an ophthalmic implant, or is a coating on a prosthesis, a guidewire, a catheter, a drug delivery implant, a stent, a vascular graft, a blood filter or extra corporeal circuitry components

25 In a drug delivery device, the active drug may be incorporated into the film by being a component of the coating latex, or by contacting the coated product, before or after curing, with a suitable drug to allow absorption or adsorption in or to the film.

The following examples illustrate the invention:

30 Example 1

The following components are used in a seeded emulsion polymerisation technique as described below:

Table 1

		%	(g)
<i>Reactor Charge</i>			
5	Demin water	59.79	179.37
	HEMA-PC	0.23	0.69
<i>Monomer Seed</i>			
10	Methyl Methacrylate	0.44	1.32
	Butyl Acrylate	0.44	1.32
<i>Initiator Seed</i>			
15	Initiator	0.02	0.06
	Demin water	2.66	7.98
<i>Monomer Feed (Controlled pumping)</i>			
20	Methyl methacrylate	7.3	21.9
	Butyl acrylate	7.3	21.9
25	Trimethoxysilylpropyl methacrylate	0.77	2.31
	Hydroxypropyl methacrylate	2.21	6.63
30	MethoxyPEG methacrylate (mwt550)	1.31	3.93
	Methacrylic acid	0.11	0.33
<i>Initiator Feed (Controlled pumping)</i>			
20	Initiator	0.07	0.21
	Demin water	10.33	30.99
25	Dimethylammoniumpropyl sulphonate, ethyl methacrylate	3.5	10.5
	<i>Mop up Feed</i>		
25	Demin water	2	6
	Initiator	0.02	0.06
<i>Alcohol addition</i>			
30	Demin water	1	3
	Benzyl alcohol	0.5	1.5
Total		100	300

The reactor charge was first loaded into the reaction vessel. The internal reaction temperature was raised to 75°C using a nitrogen purge for 45 minutes. Once the temperature was reached and the 45 minutes elapsed the nitrogen purge was switched to a blanket whilst stirring at 250 to 300rpm.

5 The monomer seed was then added and the reaction held for 10 minutes. The initiator seed was then added and the reaction held for a further 10 minutes. The internal temperature was then raised to 85°C over a period of 30 minutes allowing for any light exotherms to occur. (These are usually in the order of 2-3°C). A colour change in the reactor charge ingredients was

10 observed from a grey to a blue white colour indicating micelle formulation.

Once the 85°C temperature had been reached the monomer and initiator feeds were fed simultaneously over 150 minutes at 85°C. When the feed solutions had been added the reaction was held at 85°C for a further half hour. The initiator mop-up feed was then added over one hour at 85°C.

15 The reaction mix was then cooled to 40°C and the alcohol added. The reaction was held at 40°C for a further 10 minutes. The polymer was then filtered through an 80µm nylon mesh and then stored as a dispersion.

The particle size dispersion was measured by Disk centrifuge Photosedimentometry (DCP). This technique is based on Stokes Law. The number average diameter was 107 nm with a standard deviation of 31 nm and the weight average diameter was 181 nm with a standard deviation of 86 nm.

The product was analysed to determine the levels of residual monomer. The results are shown in Table 2 below.

**Table 2**  
**Residual Monomer**

	Monomer	ppm
5	methylmethacrylate	<30
	butylacrylate	<30
	methacrylic acid	<5
	hydroxypropylmethacrylate	<25
	silyl monomer	<5
	sulphobetaine monomer	<1800
10	MPC	<5

Example 2 - Coating Process

The product of Example 1 was diluted with demineralised water to a concentration of 10g/l (solids). The coating process, in each case, involved 15 cleaning the substrates with dichloromethane then sonicating the substrates in ethanol for two minutes. The cleaned substrates were then coated with the diluted product latex, allowed to dry for five minutes at room temperature, then placed in an oven at 70°C for four hours to cure and cross-link the film.

20 The coated substrates were subjected to various tests for biocompatibility.

2.1 Fibrinogen Adhesion

In the first test the extent of fibrinogen adhesion to the substrate is tested using the protocol substantially as described in WO-A-9301221. The 25 control, uncoated substrates were also tested and the levels of reduction are shown in Table 3.

**Table 3**  
**Fibrinogen Reduction (Fg) on Various Substrates**

Substrate	Uncoated	Coated
	Mean Absorbance @ 450nm (S.D)	
Glass	1.772 (0.200)	0.807 (0.074)
Steel	1.756 (0.223)	0.382 (0.053)
PVC	1.283 (0.227)	0.461 (0.119)
PET	1.472 (0.164)	0.499 (0.067)

10            2.2 *E.coli* Adhesion

The adhesion of *E. coli* to the substrates was tested using the following technique: The samples were incubated with *E. coli* in a nutrient broth (Oxoid) for 4 or 18 hours at 37°C. The samples were washed in phosphate buffered saline and incubated with a 1% solution of bovine serum albumin in phosphate buffered saline for 1 hour. This treatment is intended to block surface portions not coated with *E. coli* to prevent non-specific attachment of the reagent in the next step of the process. After washing in phosphate buffered saline, the sample were incubated with rabbit *E. coli* polyclonal antibody conjugated to horseradish peroxidase (1/200) for 1 hour, 15            washed for 10 minutes in phosphate buffered saline and incubated with a chromogenic substrate OPD (orthophenylenediamine) substrate buffer for a predetermined period in the range 10-20 minutes. The absorbance was read at 450 nm. This enzyme linked immunoassay result is recognised to correlate to the level of adhesion of *E. coli* cells.

20            The results are shown in Table 4.

**Table 4**  
**E-Coli Reduction on Various Substrates**

		Uncoated	Coated
	Substrate	Mean Absorbance @ 450nm (S.D)	
5	Glass	1.850 (0.173)	0.381 (0.091)
	Steel	0.439 (0.095)	0.184 (0.032)
	PVC	0.867 (0.237)	0.173 (0.091)
	PET	0.634 (0.282)	0.255 (0.016)

10 The results show that, on all four substrates, the polymers of the invention confer desirable biocompatibility as illustrated by the fibrinogen adsorption and *E. coli* adhesion tests.

### 2.3 Blood Cell Adhesion to Blood Filter Material

15 In a further performance test, the latex was used to coat a blood filter formed of polyethylene terephthalate (PET). The coated filter was contacted with whole blood and observed as described in WO-A-9301221. The product was observed under scanning electron microscope. Whilst the coated product may be seen to be contaminated by high levels of deposited material, the coated filter appears to have no adhered materials.

20 Example 3 - Other Polymers

The emulsion polymerisation process described in Example 1 was repeated but omitting one or more of the ammonium phosphate ester zwitterionic monomer, betaine comonomer and PEG monomer. The various latexes were analysed to determine the number average particle size and weight average particle size using the above techniques.

25 It was found that the omission of the sulphobetaine monomer reduced the stability of the emulsion, resulting in some build up of coagulum. The number average molecular weight following filtration of the latex product was determined to be 133 nm (standard deviation 41 nm), whilst the weight average values were 186 (78) nm.

For the polymer in which the PEG was omitted, the particle size of the latex remained low and with a low spread (number average particle size 100(21) nm, weight average 119 (33) nm), but the coated polymer had reduced wettability as judged by determining the critical wetting surface 5 tension on the filter of the type used in Example 2.

Where ammonium phosphate ester zwitterionic monomer was omitted, there was a significant reduction in latex stability with a build up of coagulum. The number average particle size was measured at 151(51) nm with the weight average being 227 (96) nm.

10 Omitting both zwitterionic monomers resulted in poor particle size control as well as higher particle sizes and a bimodal distribution of particle sizes. The number average particle size was 394(73) nm with the weight average being 433(75) nm.

15 Omitting both PEG based monomer and ammonium phosphate ester zwitterion again resulted in inadequate latex stability with a build up of coagulum. The measured particle sizes were number average 160(43) nm and weight average 210 (98) nm. This product also had poor critical wetting surface tension for the coated filter.

20 Where both betaine monomer and PEG based monomer were omitted, inadequate latex stability was achieved with a build up of coagulum. The particle sizes were greatly increased as compared to the polymer of Example 1, with number average being 510(55) nm and the weight average being 531(69) nm.

25 Omitting both zwitterionic monomers and the PEG monomer resulted in a very poor emulsion, with very high particle sizes and particle size spreads. The number average particle size was 754(211) nm with the weight average being 1012 (382) nm.

#### Example 4 - Polymer with Cationic Comonomer

30 The monomer composition and polymerisation process described above for Example 1 was adapted to incorporate 5 or 10% by weight cationic

monomer as part of the mainfeed, retaining the same relative concentrations of the remaining monomers and same overall total solids content.

The latex product was coated using the general technique described in Example 2 onto the filters used in Example 2.3 and tested for their critical 5 wetting surface tension. The results show that the CWST for the 5% cationic polymer was raised to 65 dyne/cm, as compared to 55 for the filter coated according to Example 2 and 45 dyne/cm for the uncoated filter.

A glass coverslip coated using the same general technique as in Example 2 was analysed by atomic force microscope for coating 10 smoothness, thickness and the removal force. The average coating smoothness was 6.5 nm as compared to 4.0 nm for the uncoated glass. The thickness was in the range 30 to 150 nm. The removal force was 2.850  $\mu$ N.

#### Example 5 - Core-Shell Latex Preparation

15 The reactor was loaded with 129g of distilled water and 0.69g of MPC, following which the temperature was raised to 75°C with nitrogen purge and stirring at 270 rpm. The monomer seed was added (1.32g methyl methacrylate and 1.32g butyl acrylate) and after 5 minutes the initiator seed was added (0.06g ammonium persulfate (APS) in 8g water). The reaction temperature was 20 raised to 85°C for 30 minutes after which the core monomer feed was added (15.12g methyl methacrylate, 3.78g butyl acrylate, 0.6g ethylene glycol dimethacrylate and 0.6g methoxy-polyethylene glycol methacrylate (550Mw)) together with another initiator feed (0.21g APS, 10.5g MPC in 31g water). Monomer was added over approximately an hour and immediately followed by 25 a shell feed (12.8g methyl methacrylate, 12.8g butyl acrylate, 2.3g trimethoxysilyl propyl methacrylate, 6.6g hydroxypropylmethacrylate and 3.0g of methoxy-polyethylene glycol methacrylate (550Mw) and 0.3g methacrylic acid). This was held at 85°C for a further hour before addition of an initiator spike (0.06g APS in 6.0g water) and a further 30 minutes reaction time before 30 being cooled. The solution was filtered through glass wool to remove a small amount of coagulum from the stirrer. 1.5g benzyl alcohol was added in 3.0g water as preservative.

The latex was cast onto a glass plate to form a tough film that was cured to an insoluble film upon heating at 70°C in an oven.

5       Particle analysis of the milky white liquid showed the following characteristics of the latex:


	Helium pycnometry for average density (n=3):	1.1755 cm <sup>3</sup> ± 0.0019 (1)
		1.1727 cm <sup>3</sup> ± 0.0136 (2)
		1.1707 cm <sup>3</sup> ± 0.0099 (3)
10	Disk centrifugation photosedimentometry for weight average (n=2):	0.1610 ± 0.045 µm (1)
		0.1600 ± 0.049 µm (2)
	Polydispersity (n=2):	1.238 (1)
15		1.280 (2)

**CLAIMS**

1. An emulsion polymerisation process in which a mixture of ethylenically unsaturated monomers including water insoluble monomers are polymerised in the dispersed phase of an oil-in-water emulsion in the presence of a water-soluble radical initiator, in which the monomers comprise an ammonium phosphate ester zwitterionic monomer, characterised in that the process is carried out at concentrations to give a polymer solids concentration in the product of at least 20% by weight.
2. A process according to claim 1 in which the solids concentration of the product is up to 60%, preferably in the range 25 to 50%, by weight.
3. A process according to claim 1 or claim 2 which is carried out in the substantial absence of non-polymerisable surfactants.
4. A process according to any preceding claim in which the ammonium phosphate ester zwitterionic monomer is included in an amount in the range 0.01 to 5% by weight based on the total weight of monomers, preferably 0.05 to 2% by weight.
5. A process according to any preceding claim in which the ammonium phosphate ester zwitterionic monomer has the general formula I  
$$\begin{array}{c} \text{YBX} & \text{I} \\ \text{---} & \text{---} \end{array}$$

20 in which X is the ammonium phosphate ester zwitterionic group; B is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and

25 Y is an ethylenically unsaturated group selected from  $\text{H}_2\text{C}=\text{CR}-\text{CO}-\text{A}-$ ,  $\text{H}_2\text{C}=\text{CR}-\text{C}_6\text{H}_4-\text{A}^1-$ ,  $\text{H}_2\text{C}=\text{CR}-\text{CH}_2\text{A}^2-$ ,  $\text{R}^2\text{O}-\text{CO}-\text{CR}=\text{CR}-\text{CO}-\text{O}-$ ,  $\text{RCH}=\text{CH}-\text{CO}-\text{O}-$ ,  $\text{RCH}=\text{C}(\text{COOR}^2)\text{CH}_2-\text{CO}-\text{O}-$ ,



5            A is -O- or NR<sup>1</sup>;  
           A<sup>1</sup> is selected from a bond, (CH<sub>2</sub>)<sub>n</sub>A<sup>2</sup> and (CH<sub>2</sub>)<sub>n</sub> SO<sub>3</sub><sup>-</sup> in which n is 1 to  
 12;  
           A<sup>2</sup> is selected from a bond, -O-, O-CO-, -CO-O-, -CO-NR<sup>1</sup>-, -NR<sup>1</sup>-CO,  
           -O-CO-NR<sup>1</sup>-, and -NR<sup>1</sup>-CO-O-;

10            R is hydrogen or C<sub>1-4</sub> alkyl;  
           R<sup>1</sup> is hydrogen, C<sub>1-4</sub> alkyl or BX; and  
           R<sup>2</sup> is hydrogen or C<sub>1-4</sub> alkyl.

6.           A process according to any preceding claim in which the monomers include at least 50% by weight of a hydrophobic ethylenically unsaturated polymerisable compound.

15           7.           A process according to claim 6 in which the said hydrophobic compounds are selected from C<sub>1-12</sub> alkyl(alk)acrylates and C<sub>2-12</sub>-alkyl and di-alkyl(ak)acrylamides, styrene, and mixtures thereof.

20           8.           A process according to any preceding claim in which the monomers comprise sulpho- or carboxy-betaine monomer, preferably a sulphobetaine monomer.

25           9.           A process according to claim 8 in which the weight ratio of betaine monomer to ammonium phosphate ester zwitterionic monomer is in the range (1-50):1, preferably (5-20):1.

10.           10.           A process according to any preceding claim in which the monomers comprise a hydrophilic monomer, preferably selected from C<sub>2-4</sub>-hydroxyalkyl(meth)acrylates, C<sub>1-4</sub>-hydroxyalkyl(meth)acrylamides, C<sub>1-3</sub>-alkoxy-C<sub>2-4</sub>-alkyl(meth)acrylates, C<sub>1-3</sub>-alkoxy-C<sub>2-4</sub>-alkyl(meth)acrylamides, C<sub>1-3</sub>-alkoxy-oligoethoxy(meth)acrylates C<sub>1-4</sub> -dihydroxyalkyl(meth)acrylates, N-mono- or N,N- di- C<sub>1-2</sub> alkyl (meth)acrylamides, N-vinylactams and C<sub>2-4</sub> hydroxyalkyl oligoethoxy(meth)acrylates, and mixtures thereof.

11. A process according to claim 10 in which the said hydrophilic monomer is included in an amount in the range 0.1 to 50% preferably 1 to 25% weight more preferably an amount in the range 5 to 20% by weight, based on the total weight of monomer.

5 12. A process according to any preceding claim in which the monomers include an acidic monomer, preferably in an amount to confer an acidic pH on the polymerisation mixture.


10 13. A process according to claim 12 in which the acidic monomer is acyclic acid or methacrylic acid, and it is present in an amount in the range 0.1 to 5% by weight, preferably 0.2 to 2% by weight, based on the total weight of monomers.

14. A process according to any preceding claim in which the monomers include a cationic monomer, of the general formula VIII.

$Y^2$        $B^2$        $Q$       VIII

15 in which  $Y^2$  is an ethylenically unsaturated group selected from  $H_2C=CR^{19}-CO-$   $A^8-$ ,  $H_2C=CR^{19}-C_6H_4-A^9-$ ,  $H_2C=CR^{19}-CH_2A^{10}$ ,  $R^{21}O-CO-CR^{19}=CR^{19}-CO-O-$ ,  $R^{19}CH=CH-CO-O-$ ,  $R^{19}CH=C(COOR^{21})CH_2-CO-O-$ ,

20



$A^8$  is  $-O-$  or  $-NR^{20}-$ ;

25  $A^9$  is selected from a bond,  $(CH_2)_qA^{10}$  and  $(CH_2)_qSO_3-$  in which  $q$  is 1 to 12;

$A^{10}$  is selected from a bond,  $-O-$ ,  $O-CO-$ ,  $-CO-O-$ ,  $-CO-NR^{20}-$ ,  $-NR^{20}-CO$ ,  $O-CO-NR^{20}-$ , and  $NR^{20}-CO-O-$ ;

$R^{19}$  is hydrogen or  $C_{1-4}$  alkyl;

$R^{20}$  is hydrogen,  $C_{1-4}$  alkyl or  $BX$ ;

30  $R^{21}$  is hydrogen or  $C_{1-4}$  alkyl;

$B^2$  is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and


Q is  $-N^{\circ}R^{22}_3$ ,  $-P^{\circ}R^{23}_3$  or  $-S^{\circ}R^{23}_2$  in which either the groups  $R^{22}$  are the same or different and each is hydrogen, alkyl of 1 to 6 carbon atoms, preferably methyl,  $C_{1-6}$  hydroxyalkyl, aryl, such as phenyl, or  $C_{7-12}$  aralkyl, or two of the groups  $R^{22}$  together with the nitrogen atom to which they are attached form an aliphatic heterocyclic ring containing from 5 to 7 atoms, or the three groups  $R^{22}$  together with the nitrogen atom to which they are attached form a fused ring structure containing from 5 to 7 atoms in each ring, and optionally one or more of the groups  $R^3$  is substituted by a hydrophilic functional group, and

the groups  $R^{23}$  are the same or different and each is  $R^{22}$  or a group  $OR^{22}$ , where  $R^{22}$  is as defined above *mutatis mutandis* preferably selected from quaternary ammonium alkyl(alk)acrylates and -(alk)acrylamides.

15. 15. A process according to any preceding claim, in which the monomers further include a reactive monomer having the general formula IX



in which  $Y^3$  is an ethylenically unsaturated group selected from  $H_2C=CR^{24}-CO-A^{11}-$ ,  $H_2C=CR^{24}-C_6H_4-A^{12}-$ ,  $H_2C=CR^{19}-CH_2A^{13}$ ,  $R^{26}O-CO-CR^{24}=CR-CO-O-$ ,  
20  $R^{24}CH=CH-CO-O-$ ,  $R^{24}CH=C(COOR^{26})CH_2-CO-O-$ ,



25

$A^{11}$  is  $-O-$  or  $-NR^{25}$ ;

$A^{12}$  is selected from a bond,  $(CH_2)_rA^{13}$  and  $(CH_2)_rSO_3-$  in which r is 1 to 12;

30  $A^{13}$  is selected from a bond,  $-O-$ ,  $O-CO-$ ,  $CO-O$ ,  $-CO-NR^{25}-$ ,  $-NR^{25}-CO$ ,  $-O-CO-NR^{25}-$ , and  $NR^{25}-CO-O-$ ;

$R^{24}$  is hydrogen or  $C_{1-4}$  alkyl;

$R^{25}$  is hydrogen,  $C_{1-4}$  alkyl or  $B^3Q^1$ ;

$R^{26}$  is hydrogen or  $C_{1-4}$  alkyl;

$B^3$  is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents.

5         $Q^1$  is a reactive group selected from the group consisting of aldehyde groups; silane and siloxane groups containing one or more substituents selected from halogen atoms and  $C_{1-4}$ -alkoxy groups; hydroxyl; amino; carboxyl; epoxy;  $-CHOHCH_2Hal$  (in which Hal is selected from chlorine, bromine and iodine atoms); succinimido; tosylate; triflate; imidazole carbonyl amino; 10      optionally substituted triazine groups; cinnamyl; ethylenically and acetylenically unsaturated groups; acetoacetoxy; methylol; and chloroalkylsulphone groups; acetoxy; mesylate; carbonyl di(cycloalkyl carbodiimidoyl; and oximino; preferably  $Q^1$  is a trialkoxy silyl group, such as a trimethoxysilyl group.

15      16. A process according to any preceding claim comprising the following steps:

i)        at least a portion of the ammonium phosphate ester zwitterionic monomer and a portion of the initiator are added in a first stage to the aqueous continuous phase;

20        ii)      before, simultaneously or after step i) a monomer seed mixture comprising a portion of the water-soluble monomers is added to the aqueous continuous phase;

25        iii)     after both steps i) and ii) polymerisation is initiated to form emulsion-polymerised polymer seeds;

iv)       subsequently, the remaining monomers and seed growth initiator are added to the continuous phase and seed growth polymerisation carried out.

17. A process according to claim 16 in which the composition of the combination of monomer seed mixture and zwitterionic monomer polymerised in step iii) is different to the composition of the seed growth monomers added in step iv.

30        18. A process according to claim 17 in which the monomer seed mixture consists substantially only of hydrophobic compounds as defined in claim 6 or claim 7.

19. A process according to claim 17 or claim 18 in which the seed growth monomers added in step iv) comprise any residual ammonium phosphate ester zwitterionic monomer, the residual portion of water-insoluble monomer, and optionally water-soluble monomers, preferably monomers as defined in claims 10 to 14.

20. A process according to any of claims 16 to 19 in which at least a portion of seed growth monomers are premixed before being added to the continuous phase in step iv.

21. A process according to claim 20 in which the premixed seed growth monomers are continuously fed into the continuous phase over a monomer feed period during which polymerisation continues, preferably a period in the range 5 to 1200 minutes most preferably in the range 30 to 240 minutes.

22. A process according to claim 21 in which an initiator feed, comprising at least a portion of the remaining initiator, is continuously fed into the continuous phase throughout the monomer feed period.

23. A process according to claim 21 or claim 22 in which portion of initiator is added after all the premixed seed growth monomer has been added to the continuous phase under conditions such that radicals are formed from the initiator.

24. A process according to claim 22 in which the initiator feed comprises water-soluble monomer, preferably monomer as defined in claim 8 or claim 9.

25. An emulsion polymerisation process in which a mixture of ethylenically unsaturated monomers including water-insoluble monomers and an ammonium phosphate ester zwitterionic monomer are polymerised in the dispersed phase of an oil-in-water emulsion in the presence of a water-soluble radical initiator comprising the steps:-

- 30 i) providing an aqueous solution comprising at least a portion of the ammonium phosphate ester zwitterionic monomer and a portion of the initiator;
- ii) adding to the aqueous solution of step i) a monomer seed mixture comprising at least a portion of the water-insoluble monomers;

- iii) initiating polymerisation whereby the monomers of the monomer seed mixture and the ammonium phosphate ester zwitterionic monomer are copolymerised;
- iv) providing a seed growth monomer mixture comprising the remaining water-insoluble monomers;
- 5 v) adding the seed growth mixture to the product of step iii) and initiating polymerisation of the seed growth monomers, to form a latex product.

26. A process according to claim 25 in which the latex product comprises a stable dispersion of polymer particles, preferably having a polymer concentration in the range 20 to 60% by weight.

10 27. A process according to claim 25 or 26 in which the latex product comprises a dispersed phase having a particle diameter less than 1 $\mu$ m, preferably less than 500 nm, most preferably in the range 100 to 400 nm.

28. A stable (latex) dispersion of polymer particles in an aqueous 15 continuous phase, having a polymer concentration in the range 20 to 60% by weight, based on total weight of dispersion an average particle diameter of less than 1 $\mu$ m, the polymer being formed from radical polymerised ethylenically unsaturated monomers comprising water-insoluble monomer and ammonium phosphate ester zwitterionic monomer.

20 29. A dispersion according to claim 28 further comprising suspended particulate solids selected from organic and inorganic water-insoluble materials.

30. A coating process in which a dispersion according to claim 28 or 29 is coated onto a substrate to form a liquid coating on a surface thereof, and water is removed from the liquid coating to form a stable solid polymer coating 25 on the said surface.

31. A coating process according to claim 30 in which the water is removed by evaporation and the polymer particles coalesce during the evaporation of water to form a solid polymer film on the surface.

32. A coating process according to claim 30 or claim 31 in which the 30 surface bearing the solid polymer coating is contacted with an aqueous liquid, preferably a biological liquid, more preferably selected from blood and serum.

33. A biocompatibilising process in which a substrate is biocompatibilised by coating it with a dispersion according to claim 28 or 29 and removing the water to leave a stable coating of solid polymer on the surface.

34. A polymer formed by radical polymerisation of ethylenically unsaturated monomers, in which the monomers comprise:

- 5 i) 0.1 to 25 weight% of an ammonium phosphate ester zwitterionic monomer;
- ii) 0.1 to 25 weight% of a zwitterionic comonomer different to i); and
- iii) 25 to 99% of a hydrophobic monomer.

10 35. A polymer according to claim 34 in which the hydrophobic monomer is selected from  $C_{1-12}$  alkyl(alk)acrylates and  $C_{2-12}$ -alkyl and di-alkyl(ak)acrylamides, styrene, and mixtures thereof.

36. A polymer according to claim 34 or claim 35 in which the monomers further comprise

15 iv) 0.01 to 50% hydrophilic monomer selected from  $C_{2-4}$ -hydroxyalkyl(meth)acrylates,  $C_{1-4}$ -hydroxyalkyl(meth)acrylamides,  $C_{1-3}$ -alkoxy- $C_{2-4}$ -alkyl(meth)acrylates,  $C_{1-3}$ -alkoxy- $C_{2-4}$ -alkyl(meth)acrylamides,  $C_{1-3}$ -alkoxy-oligoethoxy(meth)acrylates  $C_{1-4}$ -dihydroxyalkyl(meth)acrylates, N-mono- or N,N- di-  $C_{1-2}$  alkyl -(meth)acrylamides, N-vinylactams and  $C_{2-4}$  hydroxyalkyl oligoethoxy(meth)acrylates, and mixtures thereof.

20 37. A polymer according to claim 36, in which the hydrophilic monomer comprises a  $C_{1-3}$ -alkoxy-oligoethoxy(meth)acrylates or  $C_{2-4}$ -hydroxyalkyl-oligoethoxy(meth)acrylates, preferably an alkoxy terminated compound preferably in admixture with hydroxyalkyl(meth)acrylate or -(meth)acrylamide.


25 38. A polymer according to any of claims 34 to 37 in which the ammonium phosphate ester zwitterionic monomer is included in an amount in the range 0.01 to 5% by weight based on the total weight of monomers, preferably 0.05 to 2% by weight.

30 39. A polymer according to any of claims 34 to 38 in which the ammonium phosphate ester zwitterionic monomer has the general formula

in which X is the ammonium phosphate ester zwitterionic group;

B is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and

5 Y is an ethylenically unsaturated group selected from  $\text{H}_2\text{C}=\text{CR}-\text{CO}-\text{A}-$ ,  
 $\text{H}_2\text{C}=\text{CR}-\text{C}_6\text{H}_4-\text{A}^1-$ ,  $\text{H}_2\text{C}=\text{CR}-\text{CH}_2\text{A}^2-$ ,  $\text{R}^2\text{O}-\text{CO}-\text{CR}=\text{CR}-\text{CO}-\text{O}-$ ,  $\text{RCH}=\text{CH}-\text{CO}-\text{O}-$ ,  
 $\text{RCH}=\text{C}(\text{COOR}^2)\text{CH}_2-\text{CO}-\text{O}-$ ,



10

A is -O- or NR<sup>1</sup>;

15 12; **A<sup>1</sup>** is selected from a bond,  $(CH_2)_nA^2$  and  $(CH_2)_n SO_3^-$  in which n is 1 to

$A^2$  is selected from a bond,  $-O-$ ,  $O-CO-$ ,  $-CO-O-$ ,  $-CO-NR^1-$ ,  $-NR^1-CO-$ ,  $-O-CO-NR^1-$ , and  $-NR^1-CO-O-$ ;


R is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>1</sup> is hydrogen, C<sub>1-4</sub> alkyl or BX; and

20 R<sup>2</sup> is hydrogen or C<sub>1-4</sub> alkyl.


40. A polymer according to any of claims 34 to 39 in which the monomers include at least 50% by weight of a hydrophobic compound selected from  $C_{1-12}$  alkyl(alk)acrylates and  $C_{2-12}$ -alkyl and di-alkyl(ak)acrylamides, styrene, and mixtures thereof.

25 41. A polymer according to any of claims 34 to 40 in which the  
zwitterionic comonomer has the general formula IV



in which  $Y^1$  is an ethylenically unsaturated group selected from  $H_2C=CR^8-CO-$   
 $A^6-$ ,  $H_2C=CR^8-C_6H_4-A^3-$ ,  $H_2C=CR^8-CH_2A^4-$ ,  $R^9O-CO-CR^8=CR^8-CO-O-$ ,  
30  $R^8CH=CH-CO-O-$ ,  $R^8CH=C(COOR^9)CH_2-CO-O-$ ,


41



5

 $A^6$  is  $-O-$  or  $NR^{10}-$ ; $A^3$  is selected from a bond,  $(CH_2)_m A^4$  and  $(CH_2)_m SO_3^-$  in which  $m$  is 1 to 12;10  $A^4$  is selected from a bond,  $-O-$ ,  $O-CO-$ ,  $CO-O-$ ,  $-CO-NR^{10}-$ ,  $-NR^{10}-CO-$ ,  $-O-CO-NR^{10}-$ , and  $NR^{10}-CO-O-$ ; $R^8$  is hydrogen or  $C_{1-4}$  alkyl; $R^{10}$  is hydrogen,  $C_{1-4}$  alkyl or  $B^1 X^1$ ; $R^9$  is hydrogen or  $C_{1-4}$  alkyl;15  $B^1$  is a bond, or a straight branched alkanediyl, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and $X^1$  is a zwitterionic group other than an ammonium phosphate ester.42. A polymer according to claim 41 in which  $X^1$  is a group having the general formula V

20

25 where the groups  $R^{11}$  are the same or different and each is hydrogen or  $C_{1-4}$  alkyl and  $s$  is from 2 to 4.

43. A polymer according to any of claims 34 to 42 further comprising

v) 0.01 to 20% by weight of a reactive monomer as defined in claim

15.

30 44. A polymer according to any of claims 34 to 43 further comprising

vi) 0.01 to 5% by weight of an anionic monomer selected from fumaric acid, maleic acid, vinyl sulphonic acid, styrene sulphonic acid, acrylic acid and methacrylic acid preferably methacrylic acid.

45. A polymer according to any of claims 34 to 44 further comprising 5 0.01 to 25%, preferably, 2 to 15%, by weight of a cationic monomer as defined in claim 14.

46. A film formed of a polymer according to any of claims 34 to 45.

47. A medical device having at least one surface provided with a coating comprising a film according to claim 46.

## INTERNATIONAL SEARCH REPORT

Inten  
PCT, UD v1/05030

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C08F246/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C08F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 01221 A (BIOCOMPATIBLES LTD.) 21 January 1993 (1993-01-21) cited in the application	
A	FR 2 717 818 A (RHONE-POULENC) 29 September 1995 (1995-09-29)	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 March 2002

Date of mailing of the international search report

18/03/2002

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

## Authorized officer

Cauwenberg, C

**INTERNATIONAL SEARCH REPORT**

on on patent family members

International Search Report	Application No
PCT, 01/05030	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9301221	A 21-01-1993	AT 190988 T	15-04-2000
		AT 196482 T	15-10-2000
		AU 666485 B2	15-02-1996
		AU 2231092 A	11-02-1993
		AU 697066 B2	24-09-1998
		AU 4030995 A	22-02-1996
		AU 7993198 A	08-10-1998
		AU 7993298 A	08-10-1998
		CA 2112411 A1	21-01-1993
		DE 69230823 D1	27-04-2000
		DE 69230823 T2	27-07-2000
		DE 69231476 D1	26-10-2000
		DE 69231476 T2	25-01-2001
		DK 593561 T3	21-08-2000
		DK 810239 T3	02-01-2001
		EP 0593561 A1	27-04-1994
		EP 0810239 A2	03-12-1997
		ES 2144419 T3	16-06-2000
		ES 2150723 T3	01-12-2000
		WO 9301221 A1	21-01-1993
		JP 11166015 A	22-06-1999
		JP 3190620 B2	23-07-2001
		JP 11166018 A	22-06-1999
		JP 3233902 B2	04-12-2001
		JP 11166150 A	22-06-1999
		JP 3204956 B2	04-09-2001
		JP 2000226550 A	15-08-2000
		JP 3030086 B2	10-04-2000
		JP 7502053 T	02-03-1995
		US 6090901 A	18-07-2000
		US 6284854 B1	04-09-2001
		US 6225431 B1	01-05-2001
		US 5648442 A	15-07-1997
		US 5739236 A	14-04-1998
		US 5705583 A	06-01-1998
		US 5783650 A	21-07-1998
		AT 196303 T	15-09-2000
		DE 69231450 D1	19-10-2000
		DE 69231450 T2	18-01-2001
		DK 818479 T3	15-01-2001
		EP 0818479 A2	14-01-1998
		EP 0861858 A2	02-09-1998
		ES 2150722 T3	01-12-2000
FR 2717818	A 29-09-1995	FR 2717818 A1	29-09-1995

**THIS PAGE BLANK (USPTO)**